3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Interventions
Carboplatin
28
Cisplatin
25
pembrolizumab
25
Paclitaxel
22
Nivolumab
20
Gemcitabine
17
Pemetrexed
15
Rituximab
14
Ipilimumab
13
Cyclophosphamide
11
Dexamethasone
11
Fluorouracil
10
durvalumab
10
Capecitabine
9
Docetaxel
9
trastuzumab deruxtecan
9
Lenalidomide
8
Oxaliplatin
8
atezolizumab
8
Doxorubicin
7
daratumumab
7
osimertinib
7
Bortezomib
6
Cytarabine
6
Leucovorin
6
Sunitinib
6
Trastuzumab
6
olaparib
6
venetoclax
6
130-nm albumin-bound paclitaxel
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Cobicistat
×
1 year
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA